- ISIN
- US68622V1061
- CUSIP
- 68622V106
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- Jun 2, 2021
Highlights
- Market Cap
- $3.56B
- Enterprise Value
- $3.57B
- EPS (TTM)
- $0.38
- PE Ratio
- 35.32
- Total Revenue (TTM)
- $4.57B
- Gross Profit (TTM)
- $2.40B
- EBITDA (TTM)
- $934.32M
- Year Range
- $5.69 - $13.60
- Target Price
- $11.33
- ROA (TTM)
- 767.25%
- ROE (TTM)
- 10,050.50%
- Avg. Volume (1M)
- 3M
- Avg. Volume Value (1M)
- $35.73M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
OGN Performance Chart
Organon & Co. (OGN) is up 89.7% since the beginning of the year. At $14 per share, OGN is currently trading at its 52-week high. Investors who bought $1,000 worth of OGN shares 5 years ago would now be looking at an investment worth $573.
Loading charts...
Compare this symbol against anything
Returns By Period
Organon & Co. (OGN) has returned 89.73% so far this year and 40.20% over the past 12 months.
Organon & Co.
- 1D
- 0.00%
- 1M
- 0.00%
- 6M
- 59.30%
- YTD
- 89.73%
- 1Y
- 40.20%
- 3Y*
- -10.87%
- 5Y*
- -10.54%
- 10Y*
- —
- ALL TIME*
- -14.13%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
OGN Monthly Returns History
Based on dividend-adjusted daily data since Jun 2, 2021, OGN's average daily return is -0.02%, while the average monthly return is +0.31%. At this rate, an investment would double in approximately 18.7 years.
Historically, 50% of months were positive and 50% were negative. The best month was Apr 2026 with a return of +121.2%, while the worst month was Oct 2025 at -36.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, OGN closed higher 48% of trading days. The best single day was Apr 24, 2026 with a return of +30.9%, while the worst single day was May 1, 2025 at -26.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.11% | -14.43% | -17.83% | 121.20% | 0.83% | 1.50% | 0.07% | 89.73% | |||||
| 2025 | 4.29% | -2.41% | -0.13% | -13.16% | -28.53% | 4.99% | 0.21% | -2.68% | 13.38% | -36.80% | 14.53% | -7.00% | -50.71% |
| 2024 | 15.46% | 6.17% | 7.98% | -1.01% | 16.20% | -2.95% | 5.60% | 3.68% | -14.41% | -1.83% | -14.00% | -5.99% | 9.92% |
| 2023 | 7.88% | -17.86% | -3.96% | 4.72% | -20.22% | 7.32% | 5.62% | 1.15% | -20.95% | -14.80% | -21.54% | 27.39% | -45.12% |
| 2022 | 4.79% | 17.90% | -6.43% | -7.44% | 18.37% | -11.09% | -6.01% | -9.25% | -17.98% | 11.88% | 0.57% | 7.34% | -4.86% |
| 2021 | -17.10% | -4.13% | 17.79% | -3.25% | 12.08% | -19.75% | 4.17% | -15.13% |
Benchmark Metrics
Organon & Co. has an annualized alpha of -13.12%, beta of 0.81, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since June 02, 2021.
- This stock participated in 162.22% of S&P 500 Index downside but only 58.07% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -13.12%
- Beta
- 0.81
- R²
- 0.08
- Upside Capture
- 58.07%
- Downside Capture
- 162.22%
Return for Risk
Risk / Return Rank
OGN ranks 67 for risk / return — above 67% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Organon & Co. (OGN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| OGN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.82 | ||
| Sortino ratioReturn per unit of downside risk | -0.48 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.25 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 0.86 | 2.00 | -1.15 |
| Martin ratioReturn relative to average drawdown | 1.73 | 8.49 | -6.76 |
Dividends
Dividend History
Organon & Co. provided a 0.59% dividend yield over the last twelve months, with an annual payout of $0.08 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Dividend | $0.08 | $0.34 | $1.12 | $1.12 | $1.12 | $0.56 |
Dividend yield | 0.59% | 4.74% | 7.51% | 7.77% | 4.01% | 1.84% |
Monthly Dividends
The table displays the monthly dividend distributions for Organon & Co.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.02 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 | $0.04 | |||||
| 2025 | $0.00 | $0.28 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 | $0.02 | $0.00 | $0.34 |
| 2024 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $1.12 |
| 2023 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $1.12 |
| 2022 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $1.12 |
| 2021 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.56 |
Dividend Yield & Payout
Dividend Yield
Organon & Co. has a dividend yield of 0.59%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Organon & Co. has a payout ratio of 16.80%, which is below the market average. This means Organon & Co. returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Organon & Co.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Organon & Co. was 82.69%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Organon & Co. drawdown is 58.80%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-82.69%Mar 2026 | 4y 28d | — | 4y 5moMar 2022 - now | — |
-23.11%Jun 2021 | 5d | 4mo 18d | 4mo 23dJun 2021 - Oct 2021 | — |
-22.09%Dec 2021 | 1mo 7d | 2mo 18d | 3mo 25dNov 2021 - Feb 2022 | — |
-3.40%Jun 2021 | 1d | 1d | 1dJun 2021 - Jun 2021 | — |
-3.22%Oct 2021 | 1d | 5d | 6dOct 2021 - Nov 2021 | — |
Drawdown Indicators
| OGN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.69% | -56.78% | -25.91% |
Max Drawdown (1Y)Largest decline over 1 year | -47.96% | -9.10% | -38.86% |
Max Drawdown (3Y)Largest decline over 3 years | -74.10% | -18.90% | -55.20% |
Max Drawdown (5Y)Largest decline over 5 years | -82.69% | -25.43% | -57.26% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -58.80% | -1.58% | -57.22% |
Average DrawdownAverage peak-to-trough decline | -43.61% | -10.70% | -32.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.65% | 2.14% | +21.51% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Organon & Co. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Organon & Co. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for OGN, comparing it with other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/E ratio of 35.3. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for OGN relative to other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/S ratio of 0.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for OGN in comparison with other companies in the Drug Manufacturers - General industry. Currently, OGN has a P/B value of 3,642.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with OGN
Add Organon & Co. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with OGN